Results of two EORTC studies have been published in NEJM and the Lancet Oncology
21 Sep 2022
EORTC Completes Patient Recruitment to Study of Treatment for unresectable or metastatic melanoma
5 Aug 2022
In Memoriam: Dr Martin Charles Mihm
27 Jul 2022
Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma
24 May 2022
PRESS RELEASE: European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients
29 Jun 2021
EORTC Melanoma Group changing daily practice for cancer patients
28 Sep 2020
PRESS RELEASE: KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Compared Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
19 Sep 2020
EORTC 1325-MG/Keynote 054: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results at three-year median follow-up
29 May 2020